The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Open accessAbstract
PURPOSE: The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall survival (OS) and other secondary end points. PATIENTS AND METHODS: Patients with a deleterious or suspected deleterious germline BRCA mutation whose disease had not progressed after ≥ 16 weeks of first-line platinum-based chemotherapy were randomly assigned 3:2 to active maintenance olaparib (300 mg twice daily) or placebo. The primary end point was PFS; secondary end points included OS, time to second disease progression or death, time to first and second subsequent cancer therapies or death, time to discontinuation of study treatment or death, and safety and tolerability. RESULTS: In total, 154 patients were randomly assigned (olaparib, n = 92; placebo, n = 62). No statistically significant OS benefit was observed (median 19.0 v 19.2 months; hazard ratio [HR], 0.83; 95% CI, 0.56 to 1.22; P = .3487). Kaplan-Meier OS curves separated at approximately 24 months, and the estimated 3-year survival after random assignment was 33.9% versus 17.8%, respectively. Median time to first subsequent cancer therapy or death (HR, 0.44; 95% CI, 0.30 to 0.66; P < .0001), time to second subsequent cancer therapy or death (HR, 0.61; 95% CI, 0.42 to 0.89; P = .0111), and time to discontinuation of study treatment or death (HR, 0.43; 95% CI, 0.29 to 0.63; P < .0001) significantly favored olaparib. The HR for second disease progression or death favored olaparib without reaching statistical significance (HR, 0.66; 95% CI, 0.43 to 1.02; P = .0613). Olaparib was well tolerated with no new safety signals. CONCLUSION: Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“longer follow up data did not demonstrate a similar improvement in overall survival (OS) compared to patients who received placebo alone following platinum-based therapy88.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Friedenson B, 2005, MedGenMed, 7, 60
Cited by
Sorted by citations
Items 101–200 of 244
DNA Damage and Repair in Pancreatic Cancer—The Latest Findings
Kozłowska, M., Mik, M., Nowicki, M. O., & Śliwińska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010106 · Cited by 5
Precision medicine strategy in pancreatic ductal adenocarcinoma
Tarabay, A., Swales, L. A., Smolenschi, C., Akoury, E., Valéry, M., Fuerea, A. C., Pudlarz, T., Boige, V., Rouleau, É., Gelli, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105899 · Cited by 4
Guan, X., Li, Y., Guan, X., Fan, L., & Ying, J. (2024) · PeerJ · doi:10.7717/peerj.16805 · Cited by 4
Advances in Systemic Therapy in Pancreatic Cancer
Yu, K. H. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.002 · Cited by 4
Huang, S., Yang, J., Xie, T., Jiang, Y., Hong, Y., Liu, X., He, X., Buratto, D., Zhang, D., Zhou, R., et al. (2024) · Advanced Science · doi:10.1002/advs.202401845 · Cited by 4
Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions
Netto, D., Frizziero, M., Foy, V., McNamara, M. G., Backen, A. C., & Hubner, R. A. (2024) · Current Oncology · doi:10.3390/curroncol31090385 · Cited by 6
Milella, M., Orsi, G., Marco, M. D., Salvatore, L., Procaccio, L., Noventa, S., Bozzarelli, S., Garajová, I., Vasile, E., Giordano, G., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70364 · Cited by 4
Self-citationDreikhausen, L., Klupsch, A., Wiest, I., Xiao, Q., Schulte, N., Betge, J., Boch, T., Brochhausen, C., Gaiser, T., Hofheinz, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12261-2 · Cited by 4
Kawamoto, Y., Yamai, T., Ikezawa, K., Seiki, Y., Watsuji, K., Hirao, T., Urabe, M., Kai, Y., Takada, R., Mukai, K., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12722-8 · Cited by 4
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma
Sun, J. X., Awad, M. A., Hwang, J., & Villano, A. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15060236 · Cited by 6
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer
Safyan, R. A., & Chiorean, E. G. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102268 · Cited by 3
Emerging therapeutic advancements in pancreatic cancer: a contemporary review
Malla, M., Sakr, Y., Gupta, G., Akce, M., & El‐Rayes, B. F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03027-8 · Cited by 6
Gerdes, C., Rengarajan, S., Murugesan, K., Ross, J. S., Bartels, S., Vogel, A., & Saborowski, A. L. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.106048 · Cited by 3
Perioperative approaches for patients with biliary tract cancer
Zorigtbaatar, A., Li, Z., Magyar, C. T. J., Aceituno, L., Saborowski, A. L., Vogel, A., Grant, R. C., O'Kane, G. M., & Sapisochín, G. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01130-5 · Cited by 3
Shen, S., Ruan, Z., Jiang, B., Qiu, W., Zhang, F., & Shu, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1764452 · Cited by 4
Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond
Misirian, A., Pai, J., & Hanna, D. L. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261432058 · Cited by 3
Srkalović, G., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Ahn, E. R., Brouse, G., Chan, J. K., Mehmi, I., Khalil, M., Duvivier, H. L., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00026 · Cited by 14
Raychaudhuri, R., Cheng, H. H., Gulati, R., Schweizer, M. T., Lin, A., Yezefski, T., Khan, H. M., Yu, E. Y., Hawley, J. E., Nelson, P. S., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.04.026 · Cited by 4
Ahn, E. R., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Calfa, C. J., Alva, A. S., Suhag, V., Alese, O. B., Dotan, E., Hamid, O., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00240 · Cited by 11
Pancreatic cancer with synchronous peritoneal and hepatic metastases: A case report
Tentes, A.-A. K., Kyziridis, D., Kalakonas, A., Iliadis, A., & Fotiadou, A. (2024) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2024.109588 · Cited by 3
Urabe, M., Ikezawa, K., Kozumi, K., Kai, Y., Takada, R., Mukai, K., Nakabori, T., Uehara, H., Akita, H., & Ohkawa, K. (2024) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-024-01981-4 · Cited by 3
Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort
van Zweeden, A. A., van der Geest, L. G., Pijnappel, E. N., de Vos‐Geelen, J., van Hooft, J. E., Stommel, M. W. J., de Wit, G. F., Verheul, H. M. W., van Laarhoven, H. W. M., van der Vliet, H. J., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.03.011 · Cited by 3
von den Driesch, J., Flöttmann, J. M., Prall, F., Mullins, C. S., Linnebacher, M., & Bürtin, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1082927 · Cited by 3
Precision Oncology in Pancreatic Cancer and Future Treatment Directions
Mahmasani, L. A., & O'Reilly, E. M. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.03.002 · Cited by 2
Self-citationPrediabetes Remission and the Subsequent Risk of Pancreatic Cancer: A Nationwide Cohort Study
Park, J., Hong, J. Y., Han, K., Shen, J. J., Kwon, M., Park, Y. S., Park, J. O., & Lim, H. Y. (2025) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2025.107979 · Cited by 2
Self-citationEmerging Systemic Therapy Considerations for Pancreatic Cancer
Liang, K.-L., Guo, M. Z., & Zaidi, N. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.07.006 · Cited by 2
McGehee, C. D., Meng, X. W., Wu, X., Correia, C., Venkatachalam, A., Flatten, K. S., Peterson, K. L., Patel, A. G., Rossman, O. K., Wong, C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf990 · Cited by 2
Baghdadi, T. A., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Crysler, O., Mileham, K. F., Farrington, L. C., Adesunloye, B. A., Dublis, S. A., Astsaturov, I. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00649 · Cited by 5
Kamara, D., Niell‐Swiller, M., Bedford, S., Conlon, W., Badana, R. T., Deranteriassian, A., Siavoshi, M., Kwan, L. C., Lester, J., Donahue, T., et al. (2025) · Journal of Genetic Counseling · doi:10.1002/jgc4.70143 · Cited by 2
Buecher, B., Warcoin, M., Rolland, E., Abdullazoda, R., Guillevic, A. L., Colas, C., & Golmard, L. (2026) · European Journal of Human Genetics · doi:10.1038/s41431-026-02020-1 · Cited by 2
Epigenetic Regulators as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma
Kubiak, K., & Inkielewicz‐Stępniak, I. (2026) · Cancers · doi:10.3390/cancers18061001 · Cited by 2
Barsch, M., Godbole, I., Metzger, P., Benzing, M., Klaas, L., Decker, A., Dammer, A., Weiß, J., Dopfer, E. P., Gräßel, L., et al. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100318 · Cited by 2
Das, R., Kleinberger, J. W., Sawas, T., Wald, A. I., Bubar, R., Singh, H., Chennat, J. S., Khalid, A., Romutis, S. L., Rabinovitz, M., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.02.040 · Cited by 2
Zhu, Y., Ma, K., Hao, Q., Fu, K., Hei, F., Ning, S., Yin, Z., Guo, W., Zou, H., & Tan, Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02667-w · Cited by 2
Zhukova, L., Bordin, D. S., Dubtsova, E. A., Ilin, M. A., Kiriukova, M. A., Feoktistova, P. S., & Egorov, V. (2024) · Journal of Modern Oncology · doi:10.26442/18151434.2023.4.202541 · Cited by 2
The Role of Surgery in “Oligometastatic” Pancreas Cancer
Hewitt, D. B., & Wolfgang, C. L. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.04.009 · Cited by 2
Diagnostics and treatment of BRCA-associated cancers with olaparib — expert position statement
Kowalik, A., Chudecka-Glaz, A. M., Kufel-Grabowska, J., Skoneczna, I., & Kubiatowski, T. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.99216 · Cited by 2
Lebedeva, A., Михайлович, В. Е., Kavun, A., Belova, E., Grigoreva, T. V., Orlov, P., Subbotovskaya, A., Shipunov, M., Mashkov, O., Bilalov, F. S., et al. (2024) · World Journal of Oncology · doi:10.14740/wjon1820 · Cited by 2
Abadi, K. R. N., Dupain, C., Guillou, I., Sanchez, R., Nedara, K., Marret, G., Hescot, S., Sablin, M.-P., Ajgal, Z. C., Neuzillet, C., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100092 · Cited by 3
Sinan, H., Cunningham, D., Sleiman, E. A., Petry, D., McPhaul, T. J., Visvanathan, K., Armstrong, D. K., He, J. P., Burkhart, R. A., Pishvaian, M. J., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00494 · Cited by 4
Macarulla, T. M., Martín, A. J. M., de Castro, E. M., Trujillo, O. A. C., Cano, M. T., Castet, F., Tocino, R. V., Arias, A. F., Ghanem, I., Díaz, I. A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100116 · Cited by 2
Self-citationThreading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir, T., Moloney, C., & Mahalingam, D. (2025) · Cancers · doi:10.3390/cancers17050715 · Cited by 2
Liu, J., Ma, S., Deng, D., Yang, Y., Li, J., Zhang, Y., Yin, P., & Shang, D. (2025) · Metabolites · doi:10.3390/metabo15030207 · Cited by 3
Vornhülz, M., Angelberger, M., Sirtl, S., Philipp, A. B., Rössler, D. C., Ondrejkova, K., Markwardt, D., Heinrich, K., Westphalen, C. B., Heinemann, V., et al. (2025) · Oncology Research and Treatment · doi:10.1159/000545975 · Cited by 2
Pancreatic Adenocarcinoma: An Evolving Yet Unimpressive Treatment Landscape
Bashir, B., & Mueller, A. C. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00620 · Cited by 2
Gupta, D., Gupta, D. S., & Shetty, S. R. (2024) · Springer eBooks · doi:10.1007/978-981-97-3001-8_9 · Cited by 1
Crapé, L., Geboes, K., Kortbeek, K., Naert, E., Hoorens, A., Berrevoet, F. C., Heddeghem, N. V., & Ribeiro, S. (2024) · Acta gastro-enterologica belgica · doi:10.51821/87.4.11787 · Cited by 1
Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort
Hegenberg, S., Germing, T., Schlageter, E., Ekmekçiu, I., Christmann, J., Tannapfel, A., & Reinacher‐Schick, A. (2025) · Oncology Research and Treatment · doi:10.1159/000543997 · Cited by 1
Self-citationA cancer predisposition screening tool for young adults with cancer
Ripperger, T., & Kratz, C. P. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf150 · Cited by 1
Histopathological and genetic landscape of pancreatic ductal adenocarcinoma and its variants
Caldwell, N. J., & Zhang, M. L. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150948 · Cited by 1
Cui, Z., Lei, X., Gou, Y., Wu, Z., & Huang, X. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013566 · Cited by 1
Ripolli, A., Niccolò, N., Kauffmann, E. F., Ginesini, M., Viti, V., Lombardo, C., Vasile, E., Carla, C., Amorese, G., & Boggi, U. (2026) · Updates in Surgery · doi:10.1007/s13304-025-02502-9 · Cited by 1
Mizuno, K., Ishikawa, T., Ito, T., Takano, Y., Maeda, O., Kawashima, H., & Ando, Y. (2026) · Cancer Science · doi:10.1111/cas.70351 · Cited by 1
Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets
Murthy, D., Seyhan, A. A., den Hollander, P., Lu, S., Kuburich, N. A., Gould, C., Karam, A., Sun, K., Schupp, P. G., Safran, H., et al. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101476 · Cited by 2
Joris, S., Denys, H., Collignon, J., Rasschaert, M. A., de Roodenbeke, D. '. K., Duhoux, F. P., Canon, J.-L., Tejpar, S., Mebis, J., Decoster, L., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.107693 · Cited by 1
Bridging the gap: integrating hereditary cancer into precision oncology
Aron, M. A. R., Cruellas, M., & Balmañà, J. (2026) · European Journal of Human Genetics · doi:10.1038/s41431-026-02196-6 · Cited by 1
Neoadjuvant treatment of pancreatic ductal adenocarcinoma: present and future
Koukourakis, I. M., Desse, D., Papadimitriou, M., Konstadoulakis, M. M., Zygogianni, A. G., & PAPADIMITRIOU, C. A. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.43 · Cited by 1
Schraml, P., Aimi, F., Zoche, M., Aguilera‐Garcia, D., Arnold, F. M., Moch, H., & Hottiger, M. O. (2023) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.320 · Cited by 1
Walker, E. J., & Ko, A. H. (2023) · Cancers · doi:10.3390/cancers15143657 · Cited by 3
Lee, P., Strum, S. W., & Tsvetkova, E. M. (2023) · Case Reports in Oncological Medicine · doi:10.1155/2023/8751205 · Cited by 1
Mehra, T., Lupatsch, J. E., Koessler, T., Dedes, K. J., Siebenhüner, A. R., von Moos, R., WICKI, A. N., & Schwenkglenks, M. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301271 · Cited by 1
Yao, Z., Zhang, H., Huang, K., Huang, G., Xi, P., Jiang, L., Qin, D., Chen, F., Li, S., & Wei, R. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102206 · Cited by 1
Jin, K., & Xing, B.-C. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.06.13 · Cited by 1
Zou, X., Sidiqi, B. U., Patruni, S., Rezak, L., Hollweg, C., Kauff, N. D., & King, D. A. (2023) · medRxiv · doi:10.1101/2023.07.17.23292736 · Cited by 1
Lacalle-González, C., Lopez-Blazquez, C., Hidalgo-León, M. Á., Otieno, M. O., Sanz-Criado, L., Fernández‐Aceñero, M. J., Ortega, L. M., García‐Foncillas, J., & Martínez‐Useros, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675778 · Cited by 1
Lee, C. L., Holter, S., Borgida, A., Dodd, A., Ramotar, S., Grant, R. C., Wasson, K., Elimova, E., Jang, R. W., Moore, M. J., et al. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i45.6420
POLO-Studie: Gesamtüberleben unter Olaparib bei BRCA-positivem Pankreaskrebs
Clauss, R. M. (2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1993-4909
Personalized therapy in pancreatic cancer
Liberko, M., & Soumarová, R. (2023) · Onkologie · doi:10.36290/xon.2023.020
Metastatic pancreatic cancer and personalized therapy: a case report
Liberko, M., & Soumarová, R. (2023) · Onkologie · doi:10.36290/xon.2023.021
Exokrines Pankreaskarzinom – Welche Neuerungen bringt die neue S3-Leitlinie?
Seufferlein, T. T. W., & Kestler, A. M. R. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1932-0156
Brügel, M., Marulier, T., Evrard, C., Carlier, C., Tougeron, D., Piessen, G., Truant, S., Turpin, A., Williet, N., Botsen, D., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.06.010
Zielgerichtete Therapie des Pankreaskarzinoms
Witte, D. P., Dorman, K., Zhang, D., & Westphalen, C. B. (2023) · Die Onkologie · doi:10.1007/s00761-023-01385-y · Cited by 1
POLO-Studie: Gesamtüberleben unter Olaparib bei BRCA-positivem Pankreaskrebs
Clauss, R. M. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-2123-0977
Kornietskaya, A. L., Болотина, Л. В., Физулиевна, Е. С., Сергеевна, П. Н., Васильевна, У. Т., Игоревна, Д. Т., & Феденко, А. А. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-231
Targeted therapy and drug resistance in gastric and pancreatic cancer
Ho, X. D., Vuong, M.-H., Tran, K.-L., Nguyen, H.-Q., & Tran, Q.-T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16034-9.00007-1
Pancreatic cancer - diagnosis, risk factors and treatment. Literature review
Olczyk, K. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.17.01.016
Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer
Tsang, E. S., & Gallinger, S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2260
Therapy for Metastatic Pancreatic Cancer
Musher, B., & Zhu, H. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_4
Could Microbiome Be the Common Co-Denominator between Type 2 Diabetes and Pancreatic Cancer?
Golčić, M., & Belančić, A. (2023) · Diabetology · doi:10.3390/diabetology4040049
The Revolution in Germline DNA Testing: Actionable Takeaways from the 2023 Precision Oncology Summit
Abuali, I. A., Abrams, H. R., Khan, A. M., Riaño, I., Münster, P. N., Yadav, S., & Dubard-Gault, M. E. (2024) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.94045
Boisteau, É., Dahan, L., Williet, N., Malicot, K. L., Desrame, J., Bouché, O., Pétorin, C., Malka, D., Rebischung, C., Aparicio, T., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae079
Wang, L., & Wulf, G. M. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105158
Zielgerichtete Therapie des Pankreaskarzinoms
Witte, D. P., Dorman, K., Zhang, D., & Westphalen, C. B. (2024) · Gastro-News · doi:10.1007/s15036-024-3709-5
Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective
Feng, X., Chai, Y.-H., Jiang, K., Jiang, W., Chen, W.-C., & Pan, Y. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i11.4489
Feng, H., Chen, Z., Li, J., Feng, J., Yang, F., Meng, F., Yin, H., Guo, Y., Xu, H., Liu, Y., et al. (2025) · iScience · doi:10.1016/j.isci.2024.111693 · Cited by 2
Evrard, C., Brügel, M., Piessen, G., Roth, G. S., Williet, N., Hautefeuille, V., Trelohan, H., Müller, M., Bouché, O., & Tougeron, D. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100142
Xiao, G., Yan, J., Cai, Z., Wu, M., Zhang, R., Yang, X., Yao, Y., Xiong, Z., Ye, M., Zhang, J., et al. (2025) · medRxiv · doi:10.1101/2025.03.11.25323491
Microbial Influences: The Microbiome's Impact on Pancreatic Cancer Development and Progression
Fakruddin, M., Chowdhury, Z., Suprova, S. N., Islam, S. M. B. U., Jime, J. S., Bulbul, N., Anam, M. B., Mannan, S. B., & Shishir, M. A. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010356542250407143257
Differences in Olaparib Reactivity to Intracranial Lesions in Recurrent Breast Cancer
Ando, S., Tokumaru, Y., Niwa, Y., Mori, R., MATSUHASHI, N., & Futamura, M. (2024) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.85.1353
Wang, Y., Yusof, H. M., Aziz, M., & Chan, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15609-0.00022-2
Nassif, E. F., Javle, M. M., & Yap, T. A. (2025) · Cancer · doi:10.1002/cncr.35890
Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors
Chen, Z., Chen, G., Ma, Y., Zhao, H., Zhan, J., Huang, Y., Yang, Y., Zhao, Y., Hong, S., Zhou, T., et al. (2025) · MedComm · doi:10.1002/mco2.70272
Clinical case of therapy for BRCA1-associated metastatic pancreatic cancer
Popov, A., Baitman, T. P., Дмитриевич, С. А., Markov, P. V., Gorin, D. S., Грицкевич, А. А., Kondratyev, E. V., Kalinin, D. V., & Zhukov, N. V. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-297
Wang, J., Zheng, Q., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1558677
Molecular tumor boards in pancreatic cancer with liver metastasis: A case report.
Yan, Y., Ren, Z., Wang, W.-Y., Tang, J. P., & Zhang, Y.-W. (2025) · PubMed Central · doi:10.4254/wjh.v17.i7.106993
Sestito, M. P., Niemann, B. R., & Boone, B. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-88954-7_13
Germline BRCA2 Mutation and Lynch Syndrome in a Patient With Multiple Primary Malignancies
Puglisi, M. M., Dziarnowski, N. N., Baralo, B., & Vachhani, H. R. (2025) · Case Reports in Oncological Medicine · doi:10.1155/crom/5879510
Therapeutic pancreatic cancer biomarkers and pharmacogenetics
Langer, A., Souček, P., Vymetalkova, V., Rizzato, C., Bunduc, Ș., Nikas, I. P., Hlaváč, V., Kroupa, M., Farinella, R., Campa, D., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.002
Zhang, C., Zhang, P., Cheng, K., & Cao, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656670
Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome
Matsubayashi, H., Morizane, C., Kanai, M., Kiyozumi, Y., & Kitano, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02905-z
Metadata
- Authors
- Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E. M., Bordia, S., McGuinness, D., Cui, K., Locker, G. Y., & Golan, T.
- Affiliations
- University of Chicago (US)
- Université Paris-Saclay (FR)
- IRCCS Ospedale San Raffaele (IT)
- University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium
- Vall d'Hebron Hospital Universitari (ES)
- Fox Chase Cancer Center (US)
- Samsung Medical Center (KR)
- University College London (GB)
- Asklepios Klinik Altona (DE)
- Seoul National University (KR)
- St Josef-Hospital, Ruhr University Bochum, Bochum, Germany
- Università Cattolica del Sacro Cuore (IT)
- TUM Klinikum (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Tel Aviv University (IL)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2022-12-01
- Volume
- 40
- Issue
- 34
- Pages
- 3929-3939
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC10476841
- OpenAlex
- W4285386328
- Cited by
- 244
- References
- 39
- Citations by year
- 2026: 60 · 2025: 68 · 2024: 59 · 2023: 48 · 2022: 9
- FWCI
- 19.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-30)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- American Society of Clinical Oncology
- Alnylam Pharmaceuticals
- Celgene
- FibroGen
- Array BioPharma
- Boston Scientific Corporation
- Merck KGaA
- Taiho Pharmaceutical
- Exelixis
- Novocure
- Les Laboratories Pierre Fabre
- Halozyme
- Mylan
- Constellation Pharmaceuticals
- BeiGene
- Incyte
- MacroGenics
- Eisai
- Astellas Pharma
- European Society for Medical Oncology
- Servier
- Swedish Orphan Biovitrum
- Ipsen
- Sirtex Medical
- Aptitude Health
- National Institutes of Health (CA008748)
- Genentech
- EMD Serono
- Chugai Pharmaceutical
- National Cancer Institute (CA008748, P30- 17 CA008748, P30CA008748)
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, maintenance therapy, germline BRCA mutation, metastatic pancreatic adenocarcinoma, PARP inhibitors, overall survival, progression-free survival, platinum-based chemotherapy, secondary malignancies, PARP inhibitor resistance, treatment discontinuation, safety and tolerability
- MeSH terms
- Adenocarcinoma, Female, Germ Cells, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Pancreatic Neoplasms, Phthalazines, Piperazines, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
